Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lattice Biologics's Enterprise Value for the quarter that ended in Jun. 2021 was $3.21 Mil.
Lattice Biologics's EBIT for the trailing twelve months (TTM) ended in Jun. 2021 was $-0.35 Mil. Lattice Biologics's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2021 was -8.40%.
The historical rank and industry rank for Lattice Biologics's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
LBLTF's Earnings Yield (Joel Greenblatt) % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 0.83 * Ranked among companies with meaningful Earnings Yield (Joel Greenblatt) % only.
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Lattice Biologics's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2021 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Lattice Biologics Earnings Yield (Joel Greenblatt) % Related Terms
Lattice Biologics Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Lattice Biologics's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Lattice Biologics's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lattice Biologics Earnings Yield (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Lattice Biologics's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Lattice Biologics's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Lattice Biologicss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Sep. 2020 is calculated as
Lattice Biologics's EBIT for the trailing twelve months (TTM) ended in Jun. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.35 Mil.
What does a Earnings Yield (Joel Greenblatt) % of -8.40% mean?
Lattice Biologics (LBLTF) has a Earnings Yield (Joel Greenblatt) % of -8.40% as of Jun. 2021. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Lattice Biologics and its competitors.
Is Lattice Biologics' Earnings Yield (Joel Greenblatt) % too high?
Lattice Biologics' current Earnings Yield (Joel Greenblatt) % is -8.40%.
How does Lattice Biologics' Earnings Yield (Joel Greenblatt) % compare to ABT and MDT?
Lattice Biologics' Earnings Yield (Joel Greenblatt) % of -8.40% can be compared against companies in the Medical Devices & Instruments industry. The industry median Earnings Yield (Joel Greenblatt) % is 0.83. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median Earnings Yield (Joel Greenblatt) % among Medical Devices & Instruments companies is 0.83, based on 849 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Lattice Biologics and its competitors. For the Medical Devices & Instruments industry, the median Earnings Yield (Joel Greenblatt) % is 0.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lattice Biologics's current Earnings Yield (Joel Greenblatt) % is -8.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lattice Biologics stock overvalued right now?
Lattice Biologics (LBLTF) has a current Earnings Yield (Joel Greenblatt) % of -8.40%. The current Earnings Yield (Joel Greenblatt) % is -8.40%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Lattice Biologics (LBLTF), the current Earnings Yield (Joel Greenblatt) % is -8.40% as of Jun. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Lattice Biologics Ltd is a biologic product manufacturing company. It manufactures and markets biologic products to domestic and international markets. The company's products include ADM dermis, DBM Putty, Bone scaffold, and others, of which key revenue is derived from Bone scaffold. The biologic products are used in various applications such as enhancing fusion in spine surgery, enhancing breast reconstruction post mastectomy for breast cancer patients, sports medicine applications, promotion of bone in foot and ankle surgery, promotion of skull healing following neurosurgery, and subchondral bone defect repair in knee and other joint surgeries. The company generates its revenue from operations principally carried in the United States of America.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LBLTF has been successfully added to your 
